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INTRODUCTION 
Neonatal septicemia is defined as presence of generalized 
systemic features of sepsis associated with pure growth of 
bacteria from one or more sites 1 . This includes 
Septicaemia, Pneumonia, Meningitis, UTI etc, which may 
present in isolation or in  combination 2.A survey 
conducted by NNPD showed that   Klebsiella  is most 
common  followed by Staph aureus  and E.coli .Neonatal 
sepsis is the most common cause of neonatal deaths 
followed by extreme prematurity and birth asphyxia 3 . 
Overall incidence of sepsis is about 3.8%  in India 3. 
Mortality from neonatal sepsis is 25%  to 30% 3,4.  
Amikacin is an effective drug in neonatal septicemia but it 
has several toxic potential namely nephrotoxicity, 
ototoxicity and neurotoxicity 5. 
In our hospital settings, a case of septicemia is treated with 
aminoglycosides (AG) combined with third generation 
cephalosporins. This is the standard guidelines of treatment 
of septicaemia 2,3,4. Among the AGs, amikacin being 
extensively studied is by far a highly preferred agent 
because of its broadest spectrum, resistance to inactivating 
enzymes and least lysosomal damage 5,6. Amikacin retains 
its sensitivity and remains effective when other AG are 
resistant Besides, its tolerability profile is also relatively 
better with intermediate ototoxicity and nephrotoxicity and 
also considering cost of therapy 7.  Preterm babies can be 
treated with recommended dosage of amikacin. In case of 
septicemia, renal function is impaired and it is more 
adversely affected when it is associated with birth 
asphyxia, electrolyte imbalance 5. 
Though the duration of therapy should be 5-7days for most 
probable sepsis and 14 days for culture positive cases 6.  
But as the cost of therapy is high, and the laboratory  
procedures for monitoring such  duration of therapy is not 
possible in our hospital , short duration of 5-day therapy is 
practiced. In case of culture positive cases 14 day treatment 
and in probable sepsis 5 day treatment is practiced in this 
hospital 6,7,8. Perhaps concern over adverse safety profile of 
AG therapy in general and it’s nephrotoxicity in particular 
might have triggered the preference for such work. A baby 
of septicaemia have already deranged renal function, 
treatments with amikacin may increase the possibility of 
early renal profile changes. Nephrotoxicity is related to 
dosage, duration of therapy.  
 This regimen has in general reportedly yielded good 
results i.e mostly there is early recovery with little or no 
squeal. So aim of the study was detect early changes in 
renal profile (Safety) & to assess the efficacy of therapy 
that is being given. 
MATERIALS   &   METHODS 
The study has been conducted at the ‘special care unit’ 
baby nursery,Department of  Paediatrics, Burdwan Medical 
College. 35 diagnosed neonates of septicemia (clinical and 
Investigation based) were selected randomly for the study. 
Babies with congenital malformation, Very Low Birth 
Weight Baby, mother received aminoglycosides during 
antenatal period and mother suffering from renal disease 
were excluded from this study.  It was a hospital based 
cohort study. Permission was taken from institutional 
Ethics Committee for the study. 
Babies were regarded as control before therapy. Day of 
starting therapy is counted as day 1. Amikacin were given 
for 5 days.  Blood & 24 hours urinary samples were taken 
for day 1, day 3 and day 5.    
 Blood was collected from the neonates. From this 
collected blood serum was obtained. Serum Creatinine was 
measured by two point kinetic assay using Jaffe‘s reaction 
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9. Serum urea was   measured by Berthelot method 10. 
Serum Electrolyte: Na+, K+, has been measured by 9181 
AVL electrolyte analyzer using ion selective electrode 
(ISE) 11.  
24 hours Urine Collection was done by bag method12,13. 
Urinary creatinine clearance was considered as the marker 
of renal staus of the neonates under study. Urine creatinine 
was measured by Jaffe‘s reaction 9. 
Creatinine clearance was measured 14 using the following 
formula: 
 
 
RESULT & ANALYSIS: 
Data for day 1 was considered as control .  Day 1 means the day of starting therapy. Level of all the analytes of day 1 was 
compared with day 3 and day 5 respectively.  
Table 1:Profile of the selected cases 
Sex distribution of cases Male      20 (57%) 
Female   15(43%) 
Birth weight >2.5 kg     15  (42.85 %) 
<2.5 Kg     20 (57.15%) 
Mode of Delivery Normal   21 (60%) 
LUCS    12  (34.29%) 
Forceps  01 (2.86%) 
Breech    01 (2.86%) 
Nature of sepsis Probable sepsis     22  (62.85) 
Proven Sepsis       13  (37.15) 
 
Table 2: Differences between the mean values of selected parameters in different days of administration of 
aminoglycosides 
 Concentration of Na
+
 in 
serum (mmole/L) 
Concentration of K
+
 
in serum (mmole/L) 
Creatinine 
clearance (ml/min) 
Before administration of 
aminoglycosides (Variable 1) 
142.03 ± 5.96 5.08 ± 0.90 50.91 ± 6.38 
On 3
rd
 day of administration of 
aminoglycosides (Variable 2) 
142.66 ± 5.62 5.17 ± 0.85 49.26 ± 6.31 
On 5
th
 day of administration of 
aminoglycosides (Variable 3) 
143.37 ± 6.62 5.53 ± 0.76 48.81 ± 6.40 
Significance of Correlation between 
Variable 1 and 2 
> 0.05 >0.05 >0.05 
Significance of Correlation between 
Variable 1 and 3 
>0.05 >0.05 >0.05 
All data expressed in the form of Mean ± SD 
 
Figure 1: histogram shows the mean value of analytes in Day1 ,Day 2 & Day 3 respectively 
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DISCUSSION 
It is evident from this study that a patient of septicemia 
may have some renal function derangements and AGs have 
got nephrotoxic potential but 5 days therapy does not affect 
renal function. Though further studies are needed to define 
safe duration of therapy. Safety for treatment periods 
which are longer than 14 days has not been established 
15,16.   Aminoglycosides (AG) provided for less than 5 days 
to neonates do not produce a marked disturbance of 
creatinine clearance or tubular sodium handling 6,16.  A 
study was carried out for nephrotoxicity and evaluated 124 
patients for nephrotoxicity associated with gentamicin or 
amikacin therapy. The incidence of definite nephrotoxicity 
was 10.5% during therapy, with a mean increase in 
creatinine of 1.0 mg/100 ml (range, 0.5-3.6 mg/100 ml). 
Nephrotoxicity developed late in therapy (mean, day10 and 
the creatinine continued to increase after cessation of 
therapy for as long as nine days 17. This Study was 
conducted to see the changes in renal profile with 
Amikacin therapy in a case of neonatal septicaemia. No 
significant differences were found in 5 days therapy 
.Findings of this study will help us to use this regimen of 
AG with greater level of confidence.Further studies may be 
undertaken to have more meaningful and reliable 
information on the same problem. 
CONCLUSION 
Though potential for nephrotoxicity depends upon dose, 
coexisting medical condition, kidney function and duration 
of therapy, our study searched whether 5 days therapy is 
safe or not. In our settings, urinary enzymes detection was 
not possible, though it was more sensitive and early 
indicator, also it is noninvasive. So, considering all aspects 
of the study, it was carried out in right way.
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